Supernus Pharmaceuticals Inc. (SUPN) reported first-quarter 2026 results with revenue of $207.7 million, up 38.6% year-over-year and above the consensus estimate of $196.8 million.
Key profitability metrics:
Cash flow and balance sheet highlights:
Analyst expectations versus results and market reaction: the company beat revenue estimates, reported a loss on the bottom line versus prior-year results, and the stock was up 4.7% since market close.
Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.
Supernus Pharmaceuticals Inc. Insider Trading Activity
Supernus Pharmaceuticals Inc. insiders have traded $SUPN stock on the open market 20 times in the past 6 months. Of those trades, 0 have been purchases and 20 have been sales.
Here’s a breakdown of recent trading of $SUPN stock by insiders over the last 6 months:
- PADMANABH P. BHATT (Sr. VP of IP, CSO) has made 0 purchases and 7 sales selling 107,960 shares for an estimated $5,419,983.
- JACK A. KHATTAR (President, CEO) has made 0 purchases and 3 sales selling 35,000 shares for an estimated $1,763,124.
- FRANK MOTTOLA (SVP, Chief Tech. Ops. Officer) has made 0 purchases and 3 sales selling 21,623 shares for an estimated $1,095,223.
- GEORGES GEMAYEL has made 0 purchases and 2 sales selling 18,787 shares for an estimated $1,002,811.
- WILLIAM TODD HORICH (SVP, Commercial Operations) has made 0 purchases and 2 sales selling 8,877 shares for an estimated $483,797.
- FREDERICK M. HUDSON sold 5,369 shares for an estimated $271,725
- BETHANY SENSENIG has made 0 purchases and 2 sales selling 4,475 shares for an estimated $228,264.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.
Supernus Pharmaceuticals Inc. Hedge Fund Activity
We have seen 163 institutional investors add shares of Supernus Pharmaceuticals Inc. stock to their portfolio, and 159 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MACQUARIE GROUP LTD removed 2,531,537 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $125,817,388
- MILLENNIUM MANAGEMENT LLC added 2,293,773 shares (+662.4%) to their portfolio in Q4 2025, for an estimated $114,000,518
- WOODLINE PARTNERS LP removed 1,263,811 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $62,811,406
- CITADEL ADVISORS LLC removed 963,967 shares (-68.0%) from their portfolio in Q4 2025, for an estimated $47,909,159
- RUBRIC CAPITAL MANAGEMENT LP removed 595,366 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $29,589,690
- ASSENAGON ASSET MANAGEMENT S.A. added 530,618 shares (+inf%) to their portfolio in Q1 2026, for an estimated $27,427,644
- POINT72 ASSET MANAGEMENT, L.P. added 503,316 shares (+28.6%) to their portfolio in Q4 2025, for an estimated $25,014,805
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
Supernus Pharmaceuticals Inc. Congressional Stock Trading
Members of Congress have traded $SUPN stock 2 times in the past 6 months. Of those trades, 2 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $SUPN stock by members of Congress over the last 6 months:
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 2 times. They made 2 purchases worth up to $30,000 on 03/03, 12/11 and 0 sales.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API.
